Robert E Conway, a director of Nivalis Therapeutics, Inc., recently acquired 15,000 shares of the company. The buys took place at $2.28 per share, on May 08, 2017. Conway now owns 60,000 shares of the company. Conway operates out of Boulder, CO. Some additional info was provided as follows:
The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.244 to $2.329, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!